Abstract:Background Traditionally, the purpose of a dose-finding design in cancer is to find the maximum tolerated dose based solely on toxicity. However, for molecularly targeted agents, little toxicity may arise within the therapeutic dose range and the dose-response curves may not be monotonic. This challenges the principle that more is better, which is widely accepted for conventional chemotherapy. Methods We propose three adaptive dose-finding designs for trials evaluating molecularly targeted agents, for which the dose-response curves are unimodal or plateaued. The goal of these designs is to find the optimal biological dose, which is defined as the lowest dose with the highest rate of efficacy while safe. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose finding, the second design is nonparametric and uses the isotonic regression to identify the optimal biological dose, and the third design has the spirit of a semiparametric' approach by assuming a logistic model only locally around the current dose. Results We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies show that the nonparametric and semiparametric designs have good operating characteristics for finding the optimal biological dose. Limitations The proposed designs assume a binary endpoint. Extension of the proposed designs to ordinal and time-to-event endpoints is worth further investigation. Conclusion Among the three proposed designs, the nonparametric and semiparametric designs yield consistently good operating characteristics and thus are recommended for practical use. The software to implement these two designs is available for free download at http://odin.mdacc.tmc.edu/similar to yyuan/.

Optimal designs for dose–response models with linear effects of covariates

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Optimal designs for active controlled dose finding trials with efficacy-toxicity outcomes

A Bayesian Quasi-Likelihood Design for Identifying the Minimum Effective Dose and Maximum Utility Dose in Dose-Ranging Studies

Optimal designs for multiple treatments with unequal variances

Compound Optimum Designs for Clinical Trials in Personalized Medicine

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.

Optimum designs for clinical trials in personalized medicine when response variance depends on treatment

Optimal designs for comparing curves

Optimal designs for dose-finding experiments in toxicity studies

Covariate-adjusted response-adaptive designs for generalized linear models

Robust Optimal Design of Two-Armed Trials with Side Information

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Statistical Inference of Adaptive Randomized Clinical Trials for Personalized Medicine

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Hybrid algorithms for generating optimal designs for discriminating multiple nonlinear models under various error distributional assumptions

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Optimal experimental designs for treatment contrasts in heteroscedastic models with covariates

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

D-optimal Approximate Design for Binary Regression and Quantal Response in Toxicology Studies